S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

ContraFect Stock Forecast, Price & News

+0.03 (+0.98%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
82,317 shs
Average Volume
188,105 shs
Market Capitalization
$121.92 million
P/E Ratio
Dividend Yield
Price Target

ContraFect Stock Forecast (MarketRank)

Analyst Rating
3.25 Rating Score
168.8% Upside
$8.33 Price Target
Short Interest
5.78% of Float Sold Short
Dividend Strength
News Sentiment
0.39mentions of ContraFect in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.42) to ($0.66) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.91 out of 5 stars

Medical Sector

622nd out of 1,428 stocks

Pharmaceutical Preparations Industry

304th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

ContraFect logo

About ContraFect (NASDAQ:CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

CFRX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-20.28 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.26 per share


Free Float
Market Cap
$121.92 million
Not Optionable

ContraFect Frequently Asked Questions

Should I buy or sell ContraFect stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ContraFect stock.
View analyst ratings for ContraFect
or view top-rated stocks.

What is ContraFect's stock price forecast for 2022?

3 analysts have issued 1 year price targets for ContraFect's stock. Their CFRX stock forecasts range from $7.00 to $9.00. On average, they predict ContraFect's share price to reach $8.33 in the next year. This suggests a possible upside of 168.8% from the stock's current price.
View analysts' price targets for ContraFect
or view top-rated stocks among Wall Street analysts.

How has ContraFect's stock price performed in 2022?

ContraFect's stock was trading at $2.63 at the start of the year. Since then, CFRX shares have increased by 17.9% and is now trading at $3.10.
View the best growth stocks for 2022 here

When is ContraFect's next earnings date?

ContraFect is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for ContraFect

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) issued its earnings results on Monday, May, 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.18.
View ContraFect's earnings history

When did ContraFect's stock split? How did ContraFect's stock split work?

ContraFect shares reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

Who are ContraFect's key executives?

ContraFect's management team includes the following people:
  • Dr. Roger James Pomerantz F.A.C.P., FACP, M.D., Chairman, CEO & Pres (Age 65, Pay $1.27M)
  • Mr. Michael Messinger CPA, CPA, Chief Financial Officer (Age 47, Pay $620.25k)
  • Dr. Cara M. Cassino M.D., Chief Medical Officer and Exec. VP of R&D (Age 60, Pay $823.72k)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 53)
  • Mr. Matthew Salamone P.H.R., SPHR, VP of HR
  • Dr. Gary Woodnutt, Sr. VP of Translational Sciences & Preclinical Devel. (Age 65)

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $3.10.

How much money does ContraFect make?

ContraFect (NASDAQ:CFRX) has a market capitalization of $121.92 million. The biotechnology company earns $-20.28 million in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does ContraFect have?

ContraFect employs 38 workers across the globe.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for ContraFect is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.

This page (NASDAQ:CFRX) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.